Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Kisspeptin Dosage Protocol | PeptideDosages.com

Kisspeptin (10 mg Vial) Dosage Protocol Kisspeptin Dosage Chart Kisspeptin is dosed at 100 mcg–200 mcg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is

Kisspeptin (10 mg Vial) Dosage Protocol

Kisspeptin Dosage Chart

Kisspeptin is dosed at 100 mcg–200 mcg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.

Typical daily range: 100–200 mcg once daily (gradual titration).

Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U‑100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Kisspeptin (also known as metastin) is a naturally occurring neuroendocrine peptide that plays a pivotal role in human reproduction by stimulating gonadotropin-releasing hormone (GnRH) secretion[1]. This small peptide binds to the GPR54 receptor in the hypothalamus, triggering pulsatile GnRH release and downstream secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH)[2]. Originally identified as a metastasis-suppressor gene product, kisspeptin has become a major focus in reproductive endocrinology[3]. This educational protocol presents a once-daily subcutaneous approach for research use.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read Kisspeptin Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Weeks 1–2

100 mcg

3 units (0.03 mL)

Weeks 3–8 (or 3–12)

200 mcg

6 units (0.06 mL)

Frequency: Inject once daily subcutaneously. This schedule follows a conservative titration to assess individual response[4][5]. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

Peptide Vials (Kisspeptin, 10 mg each):

8 weeks ≈ 1 vial

12 weeks ≈ 2 vials

16 weeks ≈ 3 vials

Insulin Syringes (U‑100):

Per week: 7 syringes (1/day)

8 weeks: 56 syringes

12 weeks: 84 syringes

16 weeks: 112 syringes

Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

8 weeks (1 vial): 3 mL → 1 × 10 mL bottle

12 weeks (2 vials): 6 mL → 1 × 10 mL bottle

16 weeks (3 vials): 9 mL → 1 × 10 mL bottle

Alcohol Swabs: One for the vial stopper + one for the injection site each day.

Per week: 14 swabs (2/day)

8 weeks: 112 swabs → recommend 2 × 100‑count boxes

12 weeks: 168 swabs → recommend 2 × 100‑count boxes

16 weeks: 224 swabs → recommend 3 × 100‑count boxes

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

02

Question drills

Open a question for its connected answer.

01Frequently Asked Questions About Kisspeptin+

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.

SOURCE / peptidemind.com ↗
02What If I'm Designing a Reproductive Endocrinology Assay — Which Form Should I Use?+

Use kisspeptin-10 unless your research question specifically requires studying N-terminal degradation products. The active receptor-binding mechanism is identical, but kisspeptin-10's longer half-life reduces dosing frequency and improves reproducibility in dose-response curves. If your protocol involves measuring LH pulse dynamics over multiple hours, kisspeptin-10 allows single-injection designs rather than continuous infusion setups. The only scenario favoring kisspeptin-54 is mechanistic investigation of endogenous cleavage pathways. And even then, most labs synthesize specific intermediate fragments (kisspeptin-14, kisspeptin-13) rather than starting with the full-length peptide.

SOURCE / realpeptides.co ↗
03What If My Kisspeptin-10 Precipitates After Reconstitution?+

This indicates pH incompatibility or excessive ionic strength. Kisspeptin-10 is most soluble at neutral to slightly acidic pH (6.0–7.4) in low-salt buffers. If precipitation occurs in PBS or saline, switch to sterile water or 10 mM acetic acid, which maintains solubility without compromising peptide stability. Gently warm the vial to 25–30°C (never above 37°C) and vortex briefly. Most precipitates redissolve within 2–3 minutes. If cloudiness persists, the peptide may have undergone oxidative damage during storage (methionine oxidation at position 48 is common). Run a quick potency check via mass spectrometry or discard and replace. Oxidized peptides show 40–60% reduced receptor binding.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Does PSPeptides sell research-grade Kisspeptin?

Yes. PSPeptides offers Kisspeptin at 99%+ purity with batch-specific COAs, free shipping, same-day processing including Sundays, and Affirm/Afterpay payment options.

RESEARCH

Kisspeptin-10 Research Protocols

In vivo systemic administration: Subcutaneous or intraperitoneal injection in rodents, dose range 1–100 nmol/kg body weight. Due to rapid degradation by serum and tissue peptidases, pulsatile administration (every 60–120 minutes) using programmable osmotic mini-pumps or repeated bolus injection is superior to continuous infusion for maintaining physiological HPG axis activation. Plasma kisspeptin measurement by kisspeptin-immunoreactive ELISA validates systemic exposure. ICV administration: For hypothalamic-specific mechanistic studies, ICV injection via chronic cannula delivers Kisspeptin-10 directly to the third ventricle (0.1–10 nmol per injection), bypassing blood-brain barrier constraints and peripheral peptidase degradation. Particularly useful for dissecting ARC versus AVPV responses using targeted microinjection. Receptor specificity controls: GPR54 antagonist peptide 234 (p234) or kisspeptin receptor knockout mice (Kiss1r−/−) confirm on-target specificity of Kisspeptin-10 effects. Any metabolic or reproductive effect of Kisspeptin-10 that is abolished in Kiss1r−/− mice or by p234 co-treatment is GPR54-mediated; residual effects suggest off-target mechanisms. Metabolic phenotyping battery: Fasting glucose, insulin, HOMA-IR; glucose tolerance test (GTT, 2g/kg glucose IP); insulin tolerance test (ITT, 0.75 U/kg insulin IP); body composition (EchoMRI); plasma lipid panel (TG, HDL-C, LDL-C); plasma kisspeptin, LH, FSH, testosterone (males)/oestradiol (females) by ELISA.

POTENTIAL BENEFITS

Benefits:

Enhanced Fertility: Kisspeptin-10 can help enhance fertility in both men and women by stimulating the release of GnRH, making it a valuable tool in reproductive medicine. Puberty Regulation: Kisspeptin-10 can activate the HPG axis to support the initiation of puberty in individuals with delayed puberty. Potential in Cancer Research: Kisspeptin-10’s ability to regulate cell proliferation and metastasis offers potential therapeutic avenues in the treatment of certain cancers. Hormonal Balance: Kisspeptin-10 helps balance key reproductive hormones, which can benefit various endocrine disorders.